Rear-mounted aerodynamic structures for cargo bodies

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Stemco Lp patent solves the following problem:

Trucking is the primary means of long-distance and short-haul transportation of goods and materials in the United States, and in many other countries. Trucks often include a motorized cab where the driver sits and working on cars. cab attached to a box-like cargo section. Smaller trucks often include an integrated cargo section sitting in a unified framework which extends from the front wheels to the rear wheel assembly. The larger trucks often includes a detachable cab unit, with many driven axles, and a special trailer with a long box-like cargo units served on two or more phrases assemblies wheels. These trucks assemblages commonly called semi-trailers or tractor trailers. Most modern trucks' cabs, especially for tractor trailers, fitted with aerodynamic fairings on the roof, side and front. These fairings to help direct air over the exposed surface of the box-like cargo body, generally gave higher (a few feet) than the average roof cab. The flat, projecting front face of a cargo body is a strong source of drag on the cab roof. The use of the front-mounted aerodynamic fairings in recent years have served to significantly lower drag and, therefore, raise fuel economy for trucks, especially those traveling at high speed in the open roads.

Our analysis of this patent is as follows:

Stemco Lp’s patent US 9457847 B2 deals with Rear-mounted aerodynamic structures for cargo bodies.
A rear-mounted aerodynamic framework for taking a cargo body includes a three or four-sided structure with a deployed position to help improve flight efficiency in cargo body. The cargo body may be the body of a trailer of a tractor-trailer vehicle or trailer towed behind a vehicle like a truck. It consists of a trailer body or other body cargo well-known in the art. A destroyer run guard mounted on a top surface of the rear cargo body, as additional aerodynamic structures or as a standalone destroyer for cargo bodies. The three or four-sided rear-mounted aerodynamic structure can contain any of a variety of illustrative embodiments shown and described herein.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Compounds

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Glaxo Group Limited patent solves the following problem:

Syk is a non-receptor tyrosine kinase involved in coupling activated immunoreceptors signal consuming events that mediate diverse cellular responses, including proliferation, distinction, and phagocytosis. Syk is widely expressed in hematopoietic cells. Syk inhibitor with potential anti-inflammatory and immunomodulating activities. They inhibit SYK-mediated IgG Fc epsilon and gamma receptor and BCR receptor signaling, resulting in inhibition of activation of mast cells, macrophages, and B-cells and relevant inflammatory responses and tissue damage. Mast cells play a major role in type I hypersensitivity reactions associated with urticaria, bronchial asthma, anaphylaxis and other allergic conditions. Therefore, SYK inhibitor has attracted interest from a number of therapeutic areas, including the treatment of rheumatoid arthritis, B-cell lymphoma, asthma, rhinitis and cutaneous disorders such as acute and chronic urticaria, mastocytosis, cutaneous lupus , atopic dermatitis, autoimmune bullous conditions including Pemphigus and pemphigoid and other mast cell mediated skin disease.

Our analysis of this patent is as follows:

Glaxo Group Limited’s patent US 9447074 B2 deals with Compounds.
A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potential use in the treatment of diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for example inflammatory diseases and / or allergic conditions, in cancer therapy, especially heme malignancies, and autoimmune conditions.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Aerodynamic device for the rear of a trailer

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Trailstar International, Inc. patent solves the following problem:

The present invention relates generally to the field of aerodynamic devices to reduce drag. Particularly, the present invention relates to a flying device adapted to extend from the back of a trailer or semi-trailer container. In particular, the present invention relates to an air intake scoop and an inflatable member extending outwardly from a trailer.

Our analysis of this patent is as follows:

Trailstar International, Inc.’s patent US 9371097 B1 deals with Aerodynamic device for the rear of a trailer.
A flying device for a trailer includes an inflatable member with a back wall of a trailer adapted to inflate its rearwardly to reduce drag as the trailer pulled forwardly. The flying device further includes an air intake scoop mounted under the rear wall of the trailer in fluid communication with inflatable member filling the inflatable member in the air as the trailer moves forward.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Nutritional composition with probiotics

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The N.V. Nutricia patent solves the following problem:

Infants without intestinal flora at birth. As a result of contact with the mother during birth and subsequent feeding with human milk or formula milk, the intestinal flora rapidly. During the development, the intestinal flora is still immature and normal activities are weak. Human milk-fed infants are less afflicted by infections or diseases than formula-fed infants. Thus, human milk-fed children have less gastro-intestinal infections in terms of incidents and the duration, less atopic diseases such as allergies, eczema, less colics and cramps, and less constipation than formula-fed infants. pain came later in life, such as childhood obesity, diabetes, and asthma are related to the kind of feeding during the early stages of life, with human milk-fed infants for good .

Our analysis of this patent is as follows:

N.V. Nutricia’s patent US 9314047 B2 deals with Nutritional composition with probiotics.
A composition comprising Bifidobacterium breve, a non-digestible saccharide A and a non-digestible saccharide B, optionally with Lactobacillus paracasei and the use of said composition for the treatment and / or prevention of gastro-intestinal disorders, immune disorder and / or endocrine disorder.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Automated suggested alerts based on natural language and user profile analysis

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Domo, Inc. patent solves the following problem:

Our analysis of this patent is as follows:

Domo, Inc.’s patent US 9235978 B1 deals with Automated suggested alerts based on natural language and user profile analysis.
An alert suggestion generator to automatically suggest alert for a user based on user input. The user input may include natural language text and / or user actions that suggestion generator able to generate alert that there is a high tendency to relate, and therefore will, to the user. Each alert will have a reason for existence as the passage of time, the measure of a numeric metric, or other factors. Each alert also has a state proclamation clear how the user is announced. The alert suggestion generator to get a user profile of the user in addition to determining how alert that is most relevant to the user. The user will be queried to confirm the alert, and the alert that they set. Partial alarm will be generated and user can be queried for the trigger condition and / or state announcement needed to complete the alert.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Bifidobacterium for dust mite allergy

File for Quick & Easy Patent Protection with PowerPatent.

The N.V. Nutricia patent solves the following problem:

House dust mite (Dermatophagoides) allergy is a hypersensitive reaction to proteins in the elimination of house dust mites and can result in respiratory insufficiencies as airway obstruction and bronchial hyperreactivity. The hypersensitivity reaction is called dust mite induced respiratory lack of this document. House dust mites found in almost all households. The elimination products of dust mites can be a serious threat to the said sensitive products as well as elimination of critical ill patients. The dust mites are not visible to the unaided eye, and thus difficult to identify in the house.

Our analysis of this patent is as follows:

N.V. Nutricia’s patent US 9119414 B2 deals with Bifidobacterium for dust mite allergy.
A composition comprising Bifidobacterium breve for use in improving lung function in human subjects suffering from dust mite allergies.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Antibodies which bind to signal peptide-containing molecules

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Incyte Corporation patent solves the following problem:

Protein transport is essential for cellular function. Transport in a protein may be mediated by a peptide signal located at the amino terminal protein itself. The signal peptide consists of ten to twenty hydrophobic amino acids that target the nascent protein from ribosome to a particular membrane bound compartment such as the endoplasmic reticulum (ER). Protein target the ER to continue by way secretory or stay in any of the secretory organelles such as the ER, Golgi apparatus, or lysosomes. Proteins that transit through the secretory way be secreted into the extracellular space or left in the plasma membrane. Secreted proteins are often synthesized as inactive precursors because of the post-translation processing events during transit through the secretory way. Such events include glycosylation, phosphorylation, proteolysis, and removal of the signal peptide with a signal peptidase. The other events that occur during the transport proteins include chaperone-dependent expression and folding of nascent proteins and protein interaction with a receptor or pore complex. Examples of secreted proteins with amino terminal signal peptide described below and include the receptor, extracellular matrix molecules, cytokines, hormones, growth and diversity factor, neuropeptides, vasomediators, phosphokinases, phosphatases, phospholipases, phosphodiesterases, G and Ras-related protein, Ion channels, pedagogue / pump, proteases, and transcription factors. (Reviewed in Alberts, B. et al. (1994) Molecular Biology of the Cell, garland Publishing, New York, NY, pp. 557-560, 582-592.)

Our analysis of this patent is as follows:

Incyte Corporation’s patent US 9102745 B2 deals with Antibodies which bind to signal peptide-containing molecules.
human invention provides signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. invention also provides expression vector, host cells, antibodies, agonists and antagonists. invention also provides methods for diagnosing, treating, or preventing diseases associated with expression of HSPP.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Synbiotic mixture

File for Quick & Easy Patent Protection with PowerPatent.

The Nestec S.A. patent solves the following problem:

The human colon colony in a wide range of bacteria that have both positive and negative effects on gut physiology as well as having other systemic influences. Predominant group of bacteria found in the colon include Bacteroides, bifidobacteria, eubacteria, clostridia and lactobacilli. The bacteria present have fluctuating activities in response to substrate availability, redox potential, pH, O2 tension and distribution in the colon. In general intestinal bacteria can be divided into species that could potentially exert any harmful or beneficial effects on the host. Pathogenic effects (which can cause clostridia or Bacteroides, for example) include diarrhea, infections, liver damage, carcinogenesis and intestinal corruption. Health-promoting effects may be due to inhibition of growth and colonization of harmful bacteria, stimulation of immune functions, improve digestion and absorption of essential nutrients and synthesis of vitamins. An increase in the number and / or activity of bacteria in the genus Bifidobacterium and Lactobacillus that have health promoting properties is desirable.

Our analysis of this patent is as follows:

Nestec S.A.’s patent US 9005682 B2 deals with Synbiotic mixture.
This invention relates to a preparation containing a probiotic bacterial strain and a prebiotic mixture comprising 5-70 wt% of at least one N-acetylated oligosaccharide selected from the group consisting Ga1NAc1,3Ga11,4G1c and Ga11,6Ga1NAc1,3Ga11,4G1c, 20- 95 wt% of at least one neutral oligosaccharide selected from the group consisting Ga11,6Ga1, Ga11,6Ga11,4G1c Ga11,6Ga11,6G1c, Ga11,3Ga11,3G1c, Ga11 3Ga11,4G1c, Ga1 1,6Ga1 1,6Ga1 1, 4GIc, Ga1 1,6Ga1 1,3Ga1 1,4GIc Ga1 1,3Ga1 1,6Ga1 1,4GIc and Ga11,3Ga11,3Ga11,4G1c and 2-50 wt% at least one sialylated oligosaccharide selected from the group consisting NeuAc2,3Ga11, 4G1c and NeuAc2,6Ga11,4G1c. The invention is given to food products comprising said preparation and use in preparation for the prevention and treatment of infections.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Merck Sharp & Dohme Corp. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus pharmacologically interfering SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp.’s patent US 9006444 B2 deals with Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors.
invention provides certain phenyl formamide-containing compounds of Formula (I); or pharmaceutically acceptable salts thereof, wherein A and B as described here. invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated spleen tyrosine kinase (SYK) kinase.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Compounds

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Glaxo Group Limited patent solves the following problem:

Syk is a non-receptor tyrosine kinase involved in coupling activated immunoreceptors signal consuming events that mediate diverse cellular responses, including proliferation, distinction, and phagocytosis. Syk is widely expressed in hematopoietic cells. Syk inhibitor with potential anti-inflammatory and immunomodulating activities. They inhibit SYK-mediated IgG Fc epsilon and gamma receptor and BCR receptor signaling, resulting in inhibition of activation of mast cells, macrophages, and B-cells and relevant inflammatory responses and tissue damage. Mast cells play a major role in type I hypersensitivity reactions associated with urticaria, bronchial asthma, anaphylaxis and other allergic conditions. Therefore, SYK inhibitor has attracted interest from a number of therapeutic areas, including the treatment of rheumatoid arthritis, B-cell lymphoma, asthma, rhinitis and cutaneous disorders such as acute and chronic urticaria, mastocytosis, cutaneous lupus , atopic dermatitis, autoimmune bullous conditions including Pemphigus and pemphigoid and other mast cell mediated skin disease.

Our analysis of this patent is as follows:

Glaxo Group Limited’s patent US 8993560 B2 deals with Compounds.
A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potential use in the treatment of diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for example inflammatory diseases and / or allergic conditions, in cancer therapy, especially heme malignancies, and autoimmune conditions.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.